An AMC Principal Investigator, whose work focuses on biomarker discovery and translational cancer biomarker research, uses next-generation proteomics extensively. They expect to see an increase in data validating the utility of these proteomic technologies in the coming year, and cited a current lack of these data as a key reason why next-generation proteomics have not been adopted to a greater extent. Additionally, challenges related to analyzing FFPE tissue, sample quality control, limited assay menu offerings, bioinformatic support and the expense and turnaround time of analytical workflows are considered barriers to scaling. The stakeholder is familiar with many major vendors, and personally uses ProteinSimple, SomaLogic, MesoScale, Olink, Quanterix, and IsoPlexis, and considers the last two to be the strongest platforms in terms of technology and user experience. Key traits needed for successful platforms vary by application, but customer support and assay specificity are considered essential attributes when selecting a product.
PDF deck with summarized feedback from stakeholders
Individual PDFs of call transcripts with stakeholders
This package includes both the PDF deck and transcripts, providing a comprehensive understanding of stakeholders' views. You will receive a summarized report in the form of a PDF deck, as well as the full transcript of the discussions.
Individual call transcript of a single stakeholder discussing their views. This option is ideal for those who are interested in a specific stakeholder's perspective and insights on the topic.